Table 2.
Preclinical studies based on the use of CRISPR-Cas9 technology to provide more effective and universal CAR-T cell
| Condition | CAR | Target locus (knocked out) | Study model | Ref |
|---|---|---|---|---|
| ALL | CD19 |
Pax5 Ebf1 |
C57Bl/6 mice | [106] |
| ALL | CD19 | LDLR | NSG mice | [107] |
| Ewing sarcoma | Ganglioside G(D2) | EZH2 |
VH-64, RM-82, and WE-68 cell lines NSG mice |
[108] |
| Glioma | EGFRvIII | DGK |
U87 MG line NSG mice |
[9] |
|
Liver cancer Ovarian cancer |
Mesothelin | TGF-βRII |
HepG2 , and OVCAR3 cell line NPG mice |
[29] |
|
ALL Prostate cancer |
PSCA CD19 |
TRAC B2M PD1 |
NSG mice | [109] |
| Glioma | CD133 | PD1 |
U251 cell line NPG mice |
[110] |
| Glioma | EGFRvIII |
TRAC B2M PD1 |
U87 and U251 cell line NSG mice |
[111] |
| Glioma | EGFRvIII | PD1 | U251 cell line | [24] |
| BCL | CD19 | LAG-3 | NSG mice | [112] |
| BCL | CD22 |
TRAC PD-1 |
NALM6 cell line | [113] |
| BCL |
BCMA CD19 |
TRAC | Cell line | [7] |
| ALL | CD7 | TRAC |
MOLT-3, MOLT-4, HSB-2, and CCRF-CEM cell line NSG mice |
[114] |
| ALL | CD19 | GM-CSF |
Cell line NSG mice |
[115] |
| ALL | CD19 | GM-CSF |
NALM6 and MOLM13 cell line NSG mice |
[116] |
| BCL | CD19 | TRAC | NSG mice | [117] |
| ALL | CD19 | TRAC | NSG mice | [118] |
Note: ALL acute lymphoblastic leukemia, BCL B cell lymphoma, EGFR vIII epidermal growth factor receptor variant III, PSCA prostate stem cell antigen, BCMA B cell maturation antigen, PAX5 paired box 5, EBF1 EBF transcription factor 1, LDLR low-density lipoprotein receptor, EZH2 enhancer of zeste homolog 2, DGK diacylglycerol kinase, TGF-βRII transforming growth factor beta receptor II, TRAC T cell receptor alpha constant, B2M beta-2-microglobulin, PDCD1 or PD1 programmed cell death protein 1, LAG-3 lymphocyte activation gene 3, GM-CSF granulocyte-macrophage colony-stimulating factor